METTL3 Promotes Ovarian Carcinoma Growth and Invasion Through the Regulation of AXL Translation and Epithelial to Mesenchymal Transition
Overview
Affiliations
Objective: As the most prevalent internal modification in mammalian messenger RNA, N‑methyladenosine (mA) plays an important role in posttranscriptional gene regulation. METTL3 is a key component of the mA methyltransferase complex and has recently been shown to play important roles in cancer development and progression. The current study was aimed to explore the function and underlying mechanism of METTL3 in ovarian cancer.
Methods: METTL3 expression was assessed by immunohistochemistry in 162 ovarian carcinoma patients. Stable cell lines with METTL3 gene overexpression or knockdown were established to investigate the function of METTL3 in ovarian cancer in vitro and in vivo.
Results: METTL3 was frequently upregulated in ovarian carcinoma and that a high level of METTL3 was significantly associated with tumor grade (P = 0.001), pT status (P = 0.002), pN/pM status (P < 0.001), FIGO stage (P < 0.001), and overall survival rate (P < 0.001). Stable overexpression of METTL3 in the OVCAR3 and COV504 cell lines significantly increased cellular proliferation, focus formation, motility, invasion, and tumor formation in nude mice. Silencing METTL3 expression in the SKOV3 and HO-8910 cell lines with short hairpin RNA effectively inhibited its oncogenic function. Further study found that METTL3 promoted epithelial-mesenchymal transition (EMT) by upregulating the receptor tyrosine kinase AXL.
Conclusion: Our findings suggest that METTL3 plays very important oncogenic roles in ovarian carcinoma development and/or aggressiveness by stimulating AXL translation and EMT and that METTL3 may serve as a novel prognostic and/or therapeutic target of interest in ovarian cancer.
Epigenetic regulation in female reproduction: the impact of m6A on maternal-fetal health.
Li P, Lin Y, Ma H, Zhang J, Zhang Q, Yan R Cell Death Discov. 2025; 11(1):43.
PMID: 39904996 PMC: 11794895. DOI: 10.1038/s41420-025-02324-z.
Meng Y, Meng Y, Zheng H, Huo J, Li P, Shan Y BMC Cancer. 2024; 24(1):1455.
PMID: 39592997 PMC: 11600782. DOI: 10.1186/s12885-024-13225-2.
Li Y, Wang L, Liu J, Nie G, Yang H Front Pharmacol. 2024; 15:1491546.
PMID: 39584135 PMC: 11581872. DOI: 10.3389/fphar.2024.1491546.
RNA modification regulators as promising biomarkers in gynecological cancers.
Qi Y, Li T, Zhou Y, Hao Y, Zhang J Cell Biol Toxicol. 2024; 40(1):92.
PMID: 39472384 PMC: 11522084. DOI: 10.1007/s10565-024-09924-y.
Regulation of mA (N-Methyladenosine) methylation modifiers in solid cancers.
Singh S, Gupta S, Abhishek R, Sachan M Funct Integr Genomics. 2024; 24(6):193.
PMID: 39438339 DOI: 10.1007/s10142-024-01467-z.